ロード中...
Antiangiogenic therapies in non-small-cell lung cancer
Angiogenesis is frequent in non-small-cell lung cancer (nsclc) and is associated with more aggressive disease. Many clinical trials have evaluated the addition of antiangiogenic therapy to standard therapies for patients with nsclc. Bevacizumab, a monoclonal antibody directed against serum vascular...
保存先:
| 出版年: | Curr Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Multimed Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6001774/ https://ncbi.nlm.nih.gov/pubmed/29910647 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3747 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|